ClinConnect ClinConnect Logo
Search / Trial NCT06639971

Therapeutic Effects of Immuno-targeted Therapy Combined With or Without RT for HCC

Launched by SHANGHAI ZHONGSHAN HOSPITAL · Oct 11, 2024

Trial Information

Current as of July 22, 2025

Not yet recruiting

Keywords

Hepatocellular Carcinoma Radiotherapy Immunotherapy Target Therapy

ClinConnect Summary

This clinical trial is studying the effects of a combination of immunotherapy and targeted therapy, with or without the addition of radiotherapy, for patients with hepatocellular carcinoma (HCC), which is a type of liver cancer. The researchers want to find out if adding radiotherapy makes the treatment more effective compared to just using immunotherapy and targeted therapy alone.

To participate in this study, patients need to have a confirmed diagnosis of HCC and have received targeted therapy and immunotherapy at a specific hospital. They should also meet certain conditions related to the stage of their cancer and have complete medical records available. The study is currently not recruiting participants, but it aims to gather important information that could help improve treatment options for future patients with liver cancer. Participants will need to provide consent for their medical information and samples to be used in research, and they will be carefully monitored throughout the study.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Hepatocellular carcinoma confirmed by histopathological/cytopathological examination, or fulfilling the clinical diagnostic criteria for primary liver cancer according to the Guidelines for Diagnosis and Treatment of Primary Liver Cancer (2024 edition).
  • 2. Patients with hepatocellular carcinoma who received targeted therapy and immunotherapy at Zhongshan Hospital affiliated with Fudan University from January 1, 2017, to December 31, 2023.
  • 3. Tumor staging meeting at least one of the following criteria: 1) CNLC stage IIIa or IIIb hepatocellular carcinoma with concurrent vascular invasion or extrahepatic metastasis; 2) CNLC stage IIb hepatocellular carcinoma presenting as a localized lesion unsuitable for surgical resection or transarterial chemoembolization (TACE); 3) Presence of main portal vein or inferior vena cava tumor thrombus; 4) Disease progression observed after multiple local treatments (such as surgical resection, TACE, radiofrequency ablation, etc.).
  • 4. Availability of complete clinical and follow-up information.
  • 5. Patients have provided informed consent for donation of biological samples, allowing the donated samples and related information to be used for all medical research purposes.
  • Exclusion Criteria:
  • 1. Contraindications for radiotherapy include hepatocellular carcinoma with diffuse intrahepatic lesions, PS score of 3-4, Child-Pugh C liver function, or the presence of severe underlying medical conditions.
  • 2. Known components of the patient population include cholangiocarcinoma (ICC), mixed hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma, or fibrolamellar carcinoma.
  • 3. Exclusion criteria encompass a history of malignancies other than hepatocellular carcinoma within the past 5 years, except for limited-stage tumors considered cured, such as cervical carcinoma in situ, basal cell carcinoma, and prostate carcinoma in situ.
  • 4. Any other circumstances that the investigator deems unsuitable for participation in the study are also exclusion criteria.

About Shanghai Zhongshan Hospital

Shanghai Zhongshan Hospital is a prestigious medical institution affiliated with Fudan University, renowned for its commitment to advancing healthcare through rigorous clinical research and innovative patient care. With a focus on multidisciplinary collaboration and cutting-edge medical technologies, the hospital conducts a wide range of clinical trials aimed at improving treatment outcomes across various specialties. Its state-of-the-art facilities and highly qualified research team ensure that trials adhere to the highest ethical and scientific standards, contributing significantly to the global body of medical knowledge and enhancing patient health outcomes.

Locations

Shanghai, Shanghai, China

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported